Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-alcoholic fatty liver disease – A global public health perspective
Zobair M. Younossi
Journal of Hepatology (2018) Vol. 70, Iss. 3, pp. 531-544
Open Access | Times Cited: 1809

Showing 1-25 of 1809 citing articles:

The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Kiarash Riazi, Hassan Azhari, Jacob H Charette, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 9, pp. 851-861
Closed Access | Times Cited: 1339
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, et al.
The Lancet (2019) Vol. 394, Iss. 10215, pp. 2184-2196
Open Access | Times Cited: 1045
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Thomas G. Cotter, Mary E. Rinella
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1851-1864
Closed Access | Times Cited: 1007
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis
Andrew M. Moon, Amit G. Singal, Elliot B. Tapper
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 12, pp. 2650-2666
Open Access | Times Cited: 890
Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification
Saranya Chidambaranathan Reghupaty, Paul B. Fisher, Devanand Sarkar
Advances in cancer research (2020), pp. 1-61
Open Access | Times Cited: 630
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 586
NAFLD and cardiovascular diseases: a clinical review
Philipp Kasper, Anna Martin, Sonja Lang, et al.
Clinical Research in Cardiology (2020) Vol. 110, Iss. 7, pp. 921-937
Open Access | Times Cited: 468
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 448
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 398
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 332
Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders
Daniel M. Chopyk, Arash Grakoui
Gastroenterology (2020) Vol. 159, Iss. 3, pp. 849-863
Open Access | Times Cited: 321
Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease
Adel Hammoutène, Pierre‐Emmanuel Rautou
Journal of Hepatology (2019) Vol. 70, Iss. 6, pp. 1278-1291
Open Access | Times Cited: 278
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 71, Iss. 1, pp. 156-162
Open Access | Times Cited: 265
NAFLD: Mechanisms, Treatments, and Biomarkers
Fatiha Nassir
Biomolecules (2022) Vol. 12, Iss. 6, pp. 824-824
Open Access | Times Cited: 254
MAFLD and risk of CKD
Dan‐Qin Sun, Yan Jin, Ting-Yao Wang, et al.
Metabolism (2020) Vol. 115, pp. 154433-154433
Open Access | Times Cited: 251
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Zhen Luo, Mingfu Tian, Ge Yang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 250
Dietary Fructose and the Metabolic Syndrome
Marja‐Riitta Taskinen, Chris J. Packard, Jan Borén
Nutrients (2019) Vol. 11, Iss. 9, pp. 1987-1987
Open Access | Times Cited: 247
The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity – A longitudinal cohort study
Alina M. Allen, Stephen B. Hicks, Kristin C. Mara, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 6, pp. 1229-1236
Open Access | Times Cited: 243
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 240
Therapeutic pipeline in nonalcoholic steatohepatitis
Raj Vuppalanchi, Mazen Noureddin, Naim Alkhouri, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 6, pp. 373-392
Closed Access | Times Cited: 234
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong‐Ju Yoo, et al.
Clinical and Molecular Hepatology (2021) Vol. 27, Iss. 3, pp. 363-401
Open Access | Times Cited: 225
The clinical potential of circulating microRNAs in obesity
Chenbo Ji, Xirong Guo
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 12, pp. 731-743
Closed Access | Times Cited: 223
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 219
TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases
Miao Zhang, Yueming Ma, Xianglu Ye, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 206
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Oriol Juanola, Sebastián Martínez‐López, Rubén Francés, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 10, pp. 5227-5227
Open Access | Times Cited: 204
Page 1 - Next Page

Scroll to top